GHK-Cu + BPC-157: reconstitution guide

A common question in peptide communities is whether GHK-Cu and BPC-157 can be reconstituted together in the same vial, and how to calculate the dose when the two peptides come in different amounts. Neither compound has an approved pharmaceutical formulation for injection in any jurisdiction we cover, which means there is no regulated reconstitution protocol for either product^[1]. What follows is an explanation of the reconstitution principles involved, the dose calculation arithmetic, and the honest limits of what can and cannot be known without a clinical evidence base.

What reconstitution with bacteriostatic water involves

Lyophilised (freeze-dried) peptide vials are reconstituted by adding a sterile diluent. Bacteriostatic water for injection (BAC water) is the most commonly referenced diluent in grey-market peptide use. It contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and permits multi-dose use of the vial over several weeks when stored refrigerated. This is the same preservative used in several approved pharmaceutical products reconstituted for multi-dose parenteral use^[2]. The preservative does not prevent peptide degradation from temperature changes, repeated freeze-thaw cycles, or extended time in solution: those are separate considerations.

The volume of BAC water added determines the resulting concentration. If you add 1 ml of BAC water to a 10 mg vial of BPC-157, the concentration is 10 mg per ml, which equals 10,000 mcg per ml. If you add 2 ml, the concentration drops to 5,000 mcg per ml. The starting amount in the vial does not change; only the concentration per unit volume does.

Why the two vials differ in content

GHK-Cu is a small copper-binding tripeptide (glycyl-L-histidyl-L-lysine) with a molecular weight of approximately 340 g/mol for the peptide backbone before copper coordination^[3]. GHK-Cu vials at 50 mg therefore contain a substantially larger molar quantity than BPC-157 vials at 10 mg. BPC-157 is a 15-amino-acid synthetic peptide with a molecular weight of approximately 1420 g/mol. To put it simply: there is more GHK-Cu by mass in those vials not because of a higher potency standard, but because it is a much smaller molecule and the typical doses reported in the preclinical literature are correspondingly different in scale.

Neither compound has validated human dose data. The doses discussed online are extrapolations from animal studies, not established human therapeutic windows. A 2026 review in the American Journal of Sports Medicine that covered injectable peptide therapy concluded that for compounds including BPC-157, "indications, dosing, frequency, and duration of treatment remains unknown" in people^[4]. The same applies to injectable GHK-Cu, which has no controlled human safety trial in the published record^[1].

Reconstituting each vial separately

The straightforward approach is to reconstitute each vial individually with enough BAC water to produce a workable concentration, then draw from each vial separately. This keeps the compounds at their own known concentrations and makes dose adjustments for each independent of the other. It also avoids any question of whether combining the two compounds in a single vial affects their individual stability.

Example: add 2 ml of BAC water to the 50 mg GHK-Cu vial to get 25,000 mcg/ml. Add 2 ml to the 10 mg BPC-157 vial to get 5,000 mcg/ml. To draw a target volume, divide the target amount in mcg by the concentration in mcg/ml. These are arithmetic steps, not clinical dose recommendations.

Combining both into one vial: what is known and unknown

Transferring one reconstituted peptide solution into the other is mechanically straightforward. The practical question is whether the two compounds remain stable and retain their individual integrity in the same solution. No published peer-reviewed study has tested the stability of GHK-Cu and BPC-157 in combined solution. GHK-Cu is known to bind copper(II) ions, and Pickart and Margolina (2018) noted that GHK-Cu is sensitive to breakdown by carboxypeptidase enzymes^[3]. Whether a combined solution with BPC-157 accelerates or interferes with that degradation pathway has not been studied. In the absence of stability data, combining two grey-market compounds of unknown purity introduces an additional variable that cannot currently be evaluated.

Approved pharmaceutical combinations are tested for chemical compatibility, pH stability, and degradation products before any mixed preparation reaches a patient. Peptides sold as research chemicals have not gone through that process. The vials may contain stabilisers, residual solvents, or trace impurities that interact unpredictably when combined. That is not a reason to assert a specific risk; it is a reason to be clear that the risk profile is uncharacterised.

Dose calculation when concentrations are not 1:1

Dose calculation follows the same formula regardless of whether the two peptides are in separate vials or combined: target amount (mcg) divided by concentration (mcg/ml) equals the volume to draw (ml). The only difference with a combined vial is that the concentration for each compound must be tracked independently.

Example of the arithmetic: reconstitute the GHK-Cu vial with 2 ml of BAC water, then transfer that into the dry BPC-157 vial. Total volume is 4 ml. BPC-157 concentration: 10 mg per 4 ml = 2,500 mcg/ml. GHK-Cu concentration: 50 mg per 4 ml = 12,500 mcg/ml. Every ml drawn contains both at those fixed ratios. For any target amount, volume (ml) = target (mcg) divided by that peptide's concentration (mcg/ml). The inflexibility is the drawback: you cannot change one dose without changing the other.

Storage and stability considerations

Reconstituted peptide solutions stored in BAC water are generally kept refrigerated at 2 to 8 degrees Celsius. For grey-market BPC-157 and GHK-Cu, no compendial stability data has been published, so the appropriate use-within period is not established. Approved injectable peptide products that also use BAC water as a diluent specify refrigerated storage and a fixed use-within period: the absence of equivalent data for these unregulated vials means that boundary is unknown.

Repeated freeze-thaw cycles of reconstituted solutions are generally considered problematic for peptide integrity across the pharmaceutical literature, as physical stress can denature or aggregate small peptides. Lyophilised vials that have not yet been reconstituted can typically be stored long-term frozen. Once reconstituted in aqueous solution, freezing introduces the risk of ice crystal formation that can damage peptide structure.

Medical disclaimer

Neither GHK-Cu nor BPC-157 is approved as a medicine by the FDA, EMA, MHRA, or any national regulator in the countries we cover^[1]. This article covers reconstitution arithmetic and known pharmaceutical principles: it does not advise on doses, protocols, or whether to use these compounds. Those decisions require a clinician who can assess your specific medical situation. If you are experiencing any adverse effects from grey-market peptide use, consult a healthcare provider.